Pharma BD Deal Intelligence
Legacy neurology products became durable but minor tail assets; the deal's marquee pipeline bet (retigabine/Potiga) reached FDA approval in 2011 but was commercially withdrawn worldwide in 2017 after serious safety warnings.
Full analysis, sources & comparables →Valeant Pharmaceuticals agreed to acquire San Diego-based Xcel for $280 million in cash plus assumption of $44 million in debt, in a deal aimed at boosting its…
CEO Timothy Tyson said "The Xcel acquisition provides Valeant with access to an excellent market product portfolio and a pipeline product with significant…
GSK paid Valeant $125 million upfront plus up to $545 million in milestone payments for retigabine, "a first in class neuronal potassium channel opener for…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Valeant acquires Xcel Pharmaceuticals in 2005; brought neurology assets including rights to retigabine/ezogabine.
Legacy neurology products became durable but minor tail assets; the deal's marquee pipeline bet (retigabine/Potiga) reached FDA approval in 2011 but was commercially withdrawn worldwide in 2017 after serious safety warnings.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. (this deal) | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2005 deals · Valeant Pharmaceuticals International, Inc. deals · Neurology deals